ReviewFrontiers in oncology2020
Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetal-Maternal Interface.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.Journal of clinical medicine · 2026Review
- Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer.Frontiers in immunology · 2026Review
- Dysregulation of Key Biological Processes in Endometriosis Pathophysiology.Current molecular medicine · 2026Review
- Immunological Roles of CCL18 in Pan‑Cancer and Its Potential Value in Endometrial Cancer.Molecular biotechnology · 2025Article
- Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape.Frontiers in immunology · 2025Review
- Plasma Cells as the Key Players of IVF Failure? Unlocking the Enigma of Infertility and In Vitro Fertilization Failure in the Light of Uterine Inflammation.International journal of molecular sciences · 2024Review
- Activation of MAL2 by RAD21 inhibits the expression of MHC-I in immune evasion of endometrial cancer.Cytotechnology · 2024Article
- Review
- Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Article
- Systemic analysis of the expression and prognostic significance of USP31 in endometrial cancer.Biomolecules & biomedicine · 2023Article
- Pregnancy may have little influence on ground-glass opacities suspected for lung adenocarcinoma.Journal of cancer research and clinical oncology · 2023Article
- Roles of immune microenvironment in the female reproductive maintenance and regulation: novel insights into the crosstalk of immune cells.Frontiers in immunology · 2023Review
- CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.Frontiers in oncology · 2023Article
- Towards reproducible research in recurrent pregnancy loss immunology: Learning from cancer microenvironment deconvolution.Frontiers in immunology · 2023Article
- Review
- Bone Marrow-Derived Cells in Endometrial Cancer Pathogenesis: Insights from Breast Cancer.Cells · 2022Review
- Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression.Contrast media & molecular imaging · 2022Article
- "Iron triangle" of regulating the uterine microecology: Endometrial microbiota, immunity and endometrium.Frontiers in immunology · 2022Review
- Review
- Identification ofJournal of healthcare engineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune escape mechanisms at the base of tumor progression in endometrial cancer mimic immune tolerance mechanisms occurring at the maternal-fetal interface. The biological and immunological processes behind the maternal-fetal interface are finely tuned in time and space during embryo implantation and subsequent pregnancy stages; conversely, those behind cancer progression are often aberrant. The environment composition at the maternal-fetal interface parallels the pro-tumor microenvironment identified in many cancers, pointing to the possibility for the use of the maternal-fetal interface as a model to depict immune therapeutic targets in cancer. The framework of cancer environment signatures involved in immune adaptations, precisely timed in cancer progression, could reveal a specific "immune clock" in endometrial cancer, which might guide clinicians in patient risk class assessment, diagnostic workup, management, surgical and therapeutic approach, and surveillance strategies. Here, we review studies approaching this hypothesis, focusing on what is known so far about oncofetal similarities in immunity with the idea to individualize personalized immunotherapy targets, through the downregulation of the immune escape stage or the reactivation of the pro-inflammatory processes suppressed by the tumor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.